Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
Today, we are pleased to repost a perspective piece that ran online in the Washington Post on October 12, authored by Dr. Freda Lewis-Hall. Dr. Lewis-Hall, during her 35-year career in medicine, has been on the frontlines of health care as a clinician, researcher and leader in the biopharmaceuticals and life sciences industries. In her October 12, 2020 Washington Post op-ed, she shares her inspiration for a career that’s been dedicated to achieving a more healthful global community and offers a blueprint for how our industry can continue to strive for true health equity.
My uncle was a paraplegic because of a polio infection when he was 6 years old. By the time I reached the same age, I was so inspired by the care my uncle received that I decided I wanted to be a doctor. Years later when I entered Howard University College of Medicine in 1976, I learned that my uncle’s story of excellent care and a fruitful life well into his seventies was atypical for people of color affected by polio. Theirs were stories of racism, mistreatment and denial of care.
That settled it for me: moving from health disparity to health equity, finding a way to deliver care to those denied, delivering healing for all no matter their race, and creating healthier communities across the globe was to be my life’s work.
2020 has been a year of awakenings and re-awakenings for all people and across all industries. In this time of COVID-19 and increased awareness of racial injustice, the biopharmaceutical industry is critical to the health of all citizens of our nation and the world. More than ever, the discovery and manufacturing of medicines to treat people of varying ethnic and racial backgrounds is essential to good health outcomes. To continue achieving this, the biopharmaceutical industry must take a greater leadership role in eliminating health disparities and creating health equity. I have worked in medicine development and corporate leadership for nearly three decades. If there has ever been a time to lean in, it is now.
Nearly 30 years ago, it was surprising to both myself and many others that I would choose to pursue a career in the biopharmaceutical industry. Few in my Black and Brown community knew the industry and even fewer trusted it. But the notion of being part of an industry that discovers, develops, manufactures and delivers innovations that save or change the lives of many millions around the world was enticing. The idea that I might be able to harness the power of this industry to deliver its healing to all communities was irresistible. Over the years, I have seen many barriers overcome and challenges met. I believe that the industry is coming into its next phase of extraordinary innovation.
And now, the industry has been challenged to bring its best science and business innovation to the development of diagnostics, therapeutics and vaccines in response to a global pandemic. At the same time, we have also been challenged to address racial injustice. Can we apply our scientific and business acumen to this longstanding – and some feel intractable – problem? I think we can.
In July, the industry trade association PhRMA made a public statement regarding its commitment to having open, honest, real conversation about racial equity and what it means to have a culture of inclusion. While there are many more conversations to be had, the ones thus far have indeed been open, honest and real. A big takeaway is that Black and Brown communities need a trusted partner in the biopharmaceutical space, and that the biopharmaceutical industry is not currently viewed as trusted or as a partner. Here’s what I believe it will take to step up for these long-neglected communities:
- First, the industry needs to commit to building a workforce that represents the diverse communities that it serves now and in the future. To that end, PhRMA is urgently improving recruitment and development efforts to hire and advance the workforce to be more diverse from entry level to the board room. Companies are investing in the creation of better pathways to our industry for people of color by starting with investments in STEM, life science, data analysis and other key finance and management curriculum that serves underrepresented students. These industry commitments will help ensure increased diversity and inclusion in all dimensions of business.
- Second, the industry needs to diversify business practices so that they open the economic engine to all communities. This means adopting a comprehensive vision of expanding opportunities through collaborations, vendors, partners, suppliers, consultants and advisors. The biopharmaceutical industry should examine the best practices of other industries that have made progress in this area. Companies will be challenged to execute improved communications with diverse organizations to better understand the community and develop unique ways to meet mutual needs.
- Third, the industry must increase its efforts to advance research and policy solutions to address health disparities. The biopharmaceutical industry has an opportunity to use its research expertise to identify issues and develop new therapies and health care solutions, especially in disease areas that have a disproportionate impact on people of color. To be a trusted partner, the industry must seize the opportunity to incorporate the input of communities of color as we develop medicines, diagnostics and vaccines, and be part of interactive communications that institutionalize medical screening and disease awareness to increase the number of patients in treatment.
- Fourth, the industry must continue to diversify clinical trial populations to better reflect the patients that will use a new therapy or vaccine. Despite decades of effort, little progress has been made and we continue to see underrepresentation of minorities even in those trials where people of color bear a higher burden of disease or poorer outcomes. Given centuries of abuse by the medical system, the industry will be required to develop relationships of trust with communities of color. The industry must shape the clinical trial environment to meet the needs of diverse patients. It’s clear that communities of color do not want solutions devised for or just given to them. Rather, they wish to be a part of designing those solutions directly. We must increase the participation of clinical trial investigators and study coordinators of color and the engagement of health care centers that serve the underserved. And, we must create pathways for participation in the clinical trial process from beginning to end by including health care professionals, patient advocates, community leaders, patients and caregivers that are in and of the community.
Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity. I urge you to follow the progress at PhRMA.org/Equity.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
WHO Pandemic Agreement offers opportunities and risks for American innovators
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
What you should know about protecting your health this fall
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
Key considerations as Congress works towards PAHPA reauthorization
Between hope and despair: Improving cancer outcomes
A conversation with Dr. Mike Ybarra on the current state of COVID-19
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
PhRMA submits comments to OSTP on enhancing clinical trial diversity
What we’ve learned from three years of fighting COVID-19
U.S. must address IP and market access barriers abroad to protect American innovation
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Word of the Month: What is TRIPS?
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
Traditional HTA methods treat everyone like the “average” patient
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Potential gene therapies bring hope to patients with sickle cell disease
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
A conversation with Barry Greene, CEO of Sage Therapeutics
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Protecting U.S. innovation abroad to support economic and pandemic recovery
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Understanding breakthrough COVID-19 infections
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
The important role of antivirals in the fight against COVID-19
Understanding Long COVID-19
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Americans 12 years of age and older are eligible for COVID-19 vaccines
PhRMA hosts first stakeholder workshop on clinical trial diversity
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
A year later: Reflections on the meaning of equity
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Reflecting on Mental Health Awareness Month
American leadership on innovation policy is essential to global health progress
Patient safety is at the heart of COVID-19 vaccine R&D
PhRMA member companies share how they are improving clinical trial diversity
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
Top five issues voters want addressed in the administration’s first 100 days
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Lessons learned from COVID-19: The way we develop new medicines is changing
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Growing trend: Increased vaccine confidence
Election insights: Common ground areas to address Americans’ health care concerns
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Election insights: Voter priorities in the states
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Insights from the election: Meeting voters where they are on health care
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Guest Post: Bringing our best to the fight against COVID-19
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Just released: PhRMA members’ new clinical trial diversity principles
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Sharing rebates can improve access to medicines and increase health equity
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA will continue to advocate for equity within our industry
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
The 2020 We Work for Health Champion Awards showcase the best of our industry
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Summer reading in the age of COVID-19
Systemic racism is as real as any disease, and our industry is not immune
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
Executive order threatens R&D when we need it most to fight COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest post: A post-pandemic crisis: The mental toll on America
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
PhRMA awards $100,000 to fund projects that address health inequalities
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
What scientific experts are saying about vaccine safety
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
IP Explained: Intellectual property system working to combat COVID-19
Guest Post: What will we learn from COVID-19?
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Guest post: Securing the health care supply chain during COVID-19
To the millions affected by COVID-19
New infographic: How we are fighting COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Helping those affected by the coronavirus
ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Coronavirus
Health Equity
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasion